About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Antiretroviral Drug Safe and Effective for Patients Beginning HIV Treatment

by VR Sreeraman on August 5, 2009 at 5:02 PM
Font : A-A+

 New Antiretroviral Drug Safe and Effective for Patients Beginning HIV Treatment

Emory University researchers have found that a member of a new class of antiretroviral drugs is safe and effective for patients beginning treatment against HIV.

They came to this conclusion after analysing the results of a two-year multisite phase III clinical trial, and comparing this drug with standard antiretroviral drugs.

Advertisement

"These results provide an additional potent, well tolerated treatment option for newly diagnosed patients with HIV infection," says lead author Dr. Jeffrey Lennox professor of medicine (infectious diseases) at Emory University School of Medicine.

A research article published in the journal The Lancet reveals that the scientists found that an HIV integrase inhibitor called Raltegravir is overall as effective as widely used efavirenz, a reverse transcriptase inhibitor.
Advertisement

The researchers also observed that Raltegravir had faster onset of action and fewer adverse side effects.

During the clinical trial, the researchers combined both with two other standard retroviral drugs, tenofovir and emtricitabine.

According to the report, 566 patients from 67 medical centers on five continents were involved in the trial.

The "primary endpoint" of the trial was pushing viral levels below 50 copies per ml of blood by week 48.

The research hers said that 86 percent of the participants in the raltegravir group reached that goal, compared with 82 percent of the efavirenz group.

They further said that half the raltegravir group reached the endpoint by week four, compared with less than 20 percent for the efavirenz group.

The researchers also found the raltegravir group to encounter fewer side effects, such as headache, dizziness, and elevation in levels of cholesterol.

The authors note that raltegravir is usually taken twice a day, which may be more difficult for some patients.

However, they add, raltegravir's reduction in side effects and concerns about the ability of efavirenz to cause birth defects may be advantages for raltegravir.

Source: ANI
LIN
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Black Water: Benefits and Uses
World Hypertension Day 2022 - Measure Blood Pressure Accurately, Control It, Live Longer!
Drinking This Popular Beverage May Drop Dementia Risk
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Oral Health And AIDS Drug Toxicity AIDS/HIV AIDS/HIV - Epidemiology AIDS/HIV - Clinical Features AIDS/HIV - Health Education AIDS/HIV - Prevention And Transmission AIDS / HIV - Treatment AIDS/HIV- Lab Tests and Faqs Signature Drug Toxicity 

Most Popular on Medindia

Pregnancy Confirmation Calculator A-Z Drug Brands in India Iron Intake Calculator Selfie Addiction Calculator Blood - Sugar Chart Blood Pressure Calculator Sinopril (2mg) (Lacidipine) Nutam (400mg) (Piracetam) How to Reduce School Bag Weight - Simple Tips Color Blindness Calculator

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use